TY  - JOUR
AU  - Peters, Solange
AU  - Dziadziuszko, Rafal
AU  - Morabito, Alessandro
AU  - Felip, Enriqueta
AU  - Gadgeel, Shirish M
AU  - Cheema, Parneet
AU  - Cobo, Manuel
AU  - Andric, Zoran
AU  - Barrios, Carlos H
AU  - Yamaguchi, Masafumi
AU  - Dansin, Eric
AU  - Danchaivijitr, Pongwut
AU  - Johnson, Melissa
AU  - Novello, Silvia
AU  - Mathisen, Michael S
AU  - Shagan, Sarah M
AU  - Schleifman, Erica
AU  - Wang, Jin
AU  - Yan, Mark
AU  - Mocci, Simonetta
AU  - Voong, David
AU  - Fabrizio, David A
AU  - Shames, David S
AU  - Riehl, Todd
AU  - Gandara, David R
AU  - Mok, Tony
PY  - 2022
DO  - 10.1038/s41591-022-01933-w
UR  - http://hdl.handle.net/10668/19573
T2  - Nature medicine
AB  - Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy of first-line...
LA  - en
PB  - Nature Publishing Group
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Progression-Free Survival
KW  - Lung Neoplasms
KW  - Immunotherapy
KW  - High-Throughput Nucleotide Sequencing
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Humans
KW  - Immunotherapy
KW  - Lung Neoplasms
TI  - Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
TY  - research article
VL  - 28
ER  -